A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects

Author： Watabe Mitsuo   Cheng Yi-Fang   Nilsson Dag   Itoh Yohji   Kumagai Yuji  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.8, 2007-08, pp. : 1849-1857

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 593-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics

By Shrewsbury Stephen B.   Kori Shashidhar H.   David Miller S.   Pedinoff Andrew   Weinstein Steven  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1977-1985

Informa Healthcare

Access to resources Recommend Favorite

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

By Gottlieb Alice B.   Cooper Kevin D.   McCormick Thomas S.   Toichi Eiko   Everitt Daniel E.   Frederick Bart   Zhu Yaowei   Pendley Charles E.   Graham Martin A.   Mascelli Mary Ann  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1081-1092

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of the Selective β3‐Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Study

By  

LUTS, Vol. 7, Iss. 2, 2015-05 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 2, 2015-02 ,pp. : 242-250

John Wiley & Sons Inc

Access to resources Recommend Favorite